IVA Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.…
Industry Peers
BiotechnologyKey Statistics
About Inventiva (EPA: IVA)
›
Inventiva (EPA: IVA) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 87 employees.
The shares were at 3.165 EUR on 19 November 2026, down 8.7% over 52 weeks. Its 52-week range is 2.570 EUR to 6.200 EUR: the price is 49.0% below the high and 23.2% above the low.
Its market capitalisation is 756.76M EUR.
Inventiva reports revenue down 76.7% year over year.
It holds more cash than debt, a net cash position of 27.34M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.256 EUR is 192.4% above the current price. The next earnings report is expected on 1 April 2027.